Monocyte Subset Isolation via Cd49f Cd54 Cd11b Markers

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for isolating and optimizing monocyte subsets with enhanced antimicrobial properties are limited in effectively distinguishing and utilizing their specific capabilities for treating microbial infections.

Innovation Solution

Identification and isolation of monocyte subsets based on specific immunophenotypes and functional gene expression profiles, particularly those expressing Cd49f, Cd54, and Cd11b, which exhibit distinct capabilities in responding to and clearing bacterial and fungal infections by secreting cytokines and producing reactive oxygen species.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If monocyte subsets are isolated based on traditional markers (CD14, CD16), then isolation can be performed, but the functional heterogeneity and antimicrobial capabilities of distinct subsets cannot be effectively distinguished

Engineering Contradiction:

Improvefunctional heterogeneity detectionVSAvoidisolation methodology

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent segments monocytes into four distinct subsets (Class 1-4) based on co-expression patterns of Cd49f, Cd54, and Cd11b markers, rather than using traditional binary classification. This segmentation enables precise identification of subsets with different functional capabilities, particularly in antimicrobial responses, while providing a systematic framework for isolation and characterization.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies local quality by identifying specific marker expression patterns (Cd49f+, Cd54+, Cd11b+) that define functional characteristics of each monocyte subset. Each subset has distinct local qualities in terms of cytokine production, reactive oxygen species generation, and phagocytic activity, allowing targeted isolation based on desired functional properties.

Inventive Principle:

Principle #3Local quality

2Reliability

If monocyte subsets with enhanced antimicrobial properties are identified, then treatment efficacy improves, but isolation and characterization complexity increases

Engineering Contradiction:

Improvetreatment efficacyVSAvoidisolation and characterization process

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent performs preliminary action by establishing a comprehensive classification system and identifying key marker patterns (Cd49f, Cd54, Cd11b) before clinical application. This preliminary characterization enables straightforward isolation of therapeutic subsets without requiring complex real-time functional assays during the isolation process itself.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent changes the parameters used for monocyte classification from traditional CD14/CD16 markers to a new parameter set including Cd49f, Cd54, and Cd11b expression levels. This parameter change simplifies the isolation process while enabling more accurate selection of subsets with enhanced antimicrobial properties for therapeutic use.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12193996B2Monocyte compositions and methods for the treatment of infectious disease

Publication Date: 2025.01.14 THE GENERAL HOSPITAL CORP

AI summary

Described herein are compositions comprising subsets of monocyte having distinct functional properties and methods for using the same to treat infectious disease.